Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer

被引：36
|
作者：
Ling, Sui Wai [1 ]
de Blois, Erik [1 ]
Hooijman, Eline [1 ,2 ]
van der Veldt, Astrid [1 ,3 ]
Brabander, Tessa [1 ]
机构：
[1] Erasmus MC, Dept Radiol & Nucl Med, NL-3015 GD Rotterdam, Netherlands
[2] Erasmus MC, Dept Hosp Pharm, NL-3015 GD Rotterdam, Netherlands
[3] Erasmus MC Canc Inst, Dept Med Oncol, NL-3015 GD Rotterdam, Netherlands
来源：
PHARMACEUTICS | 2022年 / 14卷 / 10期
关键词：
actinium-225; lutetium-177; prostate-specific membrane antigen (PSMA); metastatic castration-resistant prostate cancer (mCRPC); radionuclide therapy (RNT); TARGETED ALPHA-THERAPY; MEMBRANE ANTIGEN-EXPRESSION; RADIOLIGAND THERAPY; DOSIMETRY ESTIMATE; PSMA; ADENOCARCINOMA; ACTINIUM-225; EFFICACY;
D O I：
10.3390/pharmaceutics14102166
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited. Therefore, beta and alpha radionuclide therapy (RNT) have emerged as novel treatment options for patients with mCRPC. Radioligands target the prostate-specific membrane antigen (PSMA) epitopes, which are upregulated up to a thousand times more in prostate cancer cells compared to the cells in normal tissues. For this reason, PSMA is an excellent target for both imaging and therapy. Over the past years, many studies have investigated the treatment effects of lutetium-177 labeled PSMA (Lu-177-PSMA) and actinium-225 labeled PSMA (Ac-225-PSMA) RNT in patients with mCRPC. While promising results have been achieved, this field is still in development. In this review, we have summarized and discussed the clinical data of Lu-177-PSMA and Ac-225-PSMA RNT in patients with mCRPC.
引用
收藏
页数：17
相关论文
共 50 条
  • [21] Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
    Gafita, Andrei
    Heck, Matthias M.
    Rauscher, Isabel
    Tauber, Robert
    Cala, Lisena
    Franz, Charlott
    D'Alessandria, Calogero
    Retz, Margitta
    Weber, Wolfgang A.
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (10) : 1476 - 1483
  • [22] 177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements
    Jianpeng Cao
    Yue Chen
    Mei Hu
    Wei Zhang
    Annals of Nuclear Medicine, 2021, 35 : 861 - 870
  • [23] Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis
    Satapathy, Swayamjeet
    Sood, Ashwani
    Das, Chandan Krushna
    Mittal, Bhagwant Rai
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (03) : 880 - 890
  • [24] Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
    Rasul, Sazan
    Wollenweber, Tim
    Zisser, Lucia
    Kretschmer-Chott, Elisabeth
    Grubmueller, Bernhard
    Kramer, Gero
    Shariat, Shahrokh F.
    Eidherr, Harald
    Mitterhauser, Markus
    Vraka, Chrysoula
    Langsteger, Werner
    Hacker, Marcus
    Haug, Alexander R.
    CANCERS, 2021, 13 (10)
  • [25] Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
    Barber, Thomas W.
    Singh, Aviral
    Kulkarni, Harshad R.
    Niepsch, Karin
    Billah, Baki
    Baum, Richard P.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (07) : 955 - 962
  • [26] The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer
    Ma, Jiao
    Zhang, Yu
    Yangqing, Jiangchu
    Liu, Guangfu
    Wang, Junzheng
    Zhang, Chunyin
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [27] Favorable Response of 225Ac-PSMA in the Treatment of Castration-Resistant Prostate Cancer With High Bone Metastasis Burden
    Wang, Yudi
    Hua, Qingchu
    Zhang, Yu
    Wang, Wei
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (07) : 674 - 676
  • [28] Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
    Gafita, Andrei
    Calais, Jeremie
    Grogan, Tristan R.
    Hadaschik, Boris
    Wang, Hui
    Weber, Manuel
    Sandhu, Shahneen
    Kratochwil, Clemens
    Esfandiari, Rouzbeh
    Tauber, Robert
    Zeldin, Anna
    Rathke, Hendrik
    Armstrong, Wesley R.
    Robertson, Andrew
    Thin, Pan
    D'Alessandria, Calogero
    Rettig, Matthew B.
    Delpassand, Ebrahim S.
    Haberkorn, Uwe
    Elashoff, David
    Herrmann, Ken
    Czernin, Johannes
    Hofman, Michael S.
    Fendler, Wolfgang P.
    Eiber, Matthias
    LANCET ONCOLOGY, 2021, 22 (08): : 1115 - 1125
  • [29] Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer One Center Results
    Ozkan, Ahu
    Ucar, Burcu
    Seymen, Huelya
    Yarar, Yasemin Yildiz
    Falay, Fikri Okan
    Demirkol, Mehmet Onur
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (04) : 288 - 291
  • [30] Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer
    Perrone, Elisabetta
    Giordano, Alessandro
    Calcagni, Maria Lucia
    Leccisotti, Lucia
    Moretti, Roberto
    Eismant, Aleksandr
    Ghai, Kriti
    Parkar, Tanay
    Mishra, Aditi
    Heidenreich, Axel
    Wirtz, Ralph M.
    Mueller, Joerg
    Greifenstein, Lukas
    Baum, Richard P.
    CANCERS, 2025, 17 (03)
12345